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http://www.wjso.com/content/12/1/352RESEARCH Open AccessNeogenin expression is inversely associated with
breast cancer grade in ex vivo
Wanying Xing1, Qiang Li2, Rangjuan Cao2 and Zheli Xu1*Abstract
Background: Neogenin is closely related to the human tumor suppressor gene deleted in colorectal cancer and
plays a role in mammary morphogenesis. This study aimed to assess neogenin expression in breast cancer for any
clinically significant association.
Methods: A total of 54 breast cancer patients who underwent modified radical mastectomy were enrolled for
immunohistochemical and quantitative real-time PCR analysis of neogenin expression in their cancerous breast
tissues in comparison to matching distant non-cancerous tissues.
Results: The data showed that the neogenin protein was either strongly or moderately expressed in the cytoplasm of
the distant non-cancerous cells. In contrast, neogenin protein was either weakly or not expressed in the cytoplasm of
51/54 (94.4%) breast cancer cells, among which 13 breast cancer cases did not express neogenin protein at all (13/54,
24.1%). Similarly, levels of neogenin mRNA were significantly lower in breast cancer tissues than that of the matched
distant non-cancerous tissues (51/54, 94.4%). Neogenin expression was inversely associated with breast cancer grade;
that is, grade III breast cancer expressed much less neogenin than grade I-II (P < 0.05).
Conclusions: This study indicates that neogenin expression in breast cancer tissues is inversely associated with tumor
grade.
Keywords: Neogenin, breast cancer, histological grading, predictive biomarkersBackground
Breast cancer is the most common cancer in women in
both developed and developing countries [1]. In China,
breast cancer accounts for 14.2% of all malignant tumors
in Chinese women, while the percentage is 26.4% in the
USA [2]. Despite advancements in early detection and
treatment of breast cancer, breast cancer is still the lea-
ding cause of cancer-related death among women in the
world [3,4]. Clinically, tumor stage, histological grade,
and different tumor markers have been useful in evalua-
ting and predicting breast cancer progression, treatment
response, and prognosis [5]. Recently, researchers have
tried to classify breast cancer based on the profile of dif-
ferential gene expression to advance individualized treat-
ment, and to help predict prognosis of the patients [6].
For example, breast cancer with estrogen receptor (ER)* Correspondence: eryaoqi@126.com
1Department of Breast Surgery, China-Japan Union Hospital of Jilin University,
Changchun 130033, China
Full list of author information is available at the end of the article
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unless otherwise stated.and progesterone receptor (PR) expression has been
associated with sensitivity to endocrine therapy [7,8],
whereas human epidermal growth factor-2 (HER2)-over-
expressed or HER-2-amplified breast cancer is resistant
to endocrine therapy [9], but is more sensitive to trastu-
zumab [10,11]. ER, PR and HER-2-negative breast
cancer (that is, triple negative breast cancer) [12] has the
worst prognosis among all subtypes of breast cancer. To
date, early detection is still key for survival of patients.
Thus, identification and evaluation of novel tumor
markers could help with early detection of breast cancer
or the development of novel therapeutic targets for
treatment of breast cancer patients.
Towards this end, our study focused on the protein
neogenin, which is closely related to the human tumor
suppressor gene deleted in colorectal cancer (DCC) [12]
and which plays a role in mammary morphogenesis [13].
Neogenin has been shown to be expressed in a wided. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cells actively proliferate and migrate. Neogenin ligands
include netrins and the family of repulsive guidance
molecules (RGM) [14-16]. Neogenin has various functions
dependent on its activation by different ligands; for ex-
ample, after binding to netrin-1, neogenin can improve
axon guidance by chemoattractively promoting cell migra-
tion and adhesion, whereas when binding RGM?, neogenin
functions as a chemorepellant for cells [17]. Overall, the
neogenin-ligand interaction can influence cell migration
[17], tissue morphogenesis [18,19], tumor growth [20,21]
and regulation of inflammation [22]. However, neogenin
can induce apoptosis of certain types of cells when its
ligands are absent. In the mammary gland, it has been
shown that netrin-1-activated neogenin can stabilize
multipotent progenitor cap cells during mammary gland
morphogenesis [22,23], while another study showed that
neogenin expression was inversely associated with mam-
mary gland tumorigenesis [23]. However, in the original
gene cloning and screening study [13], there was no alter-
ation in neogenin expression observed in more than 50
types of human cancer cell lines, including breast cancer.
In this study, we measured expression of neogenin mRNA
and protein in breast cancer and compared this to expres-
sion in distant non-cancerous tissues in order to establish
whether this receptor is clinically associated with breast
cancer.
Methods
Breast cancer tissue samples
In this study, we recruited a total of 54 female primary
breast cancer patients with a mean age of 51 years
(range 30 to 75 years of age) who underwent modified
radical mastectomy at the China-Japan Union Hospital
of Jilin University between June 2012 and February
2013. None of these patients received preoperative
chemo-, radiation-, or endocrine therapy. This study
was approved by The Ethics Committee of Jilin University
and all patients provided informed consent. Tissue
specimens of breast cancer lesions and distant normal
mammary glands were collected during the surgery,
snap-frozen in liquid nitrogen, and stored at −80°C
before use. Tumors were diagnosed and classified
according to the American Joint Committee on Cancer
breast cancer TNM staging system [24] and the World
Health Organization breast cancer histology and sub-
types classifications [25].
Immunohistochemical staining
Formalin-fixed and paraffin-embedded tissue blocks
were cut into 5 μm thick tissue sections for im-
munohistochemical staining of ER, PR, HER2, Ki67,
p53, and neogenin. Tissue sections were deparaffinized
and re-hydrated routinely and then subjected to antigenretrieval by boiling in a pressure cooker in 10 mM citrate
buffer, pH 6.0 at a pressure of 0.12 MPa for 90 seconds.
After treatment with 3% H2O2 for 30 minutes, the sections
were incubated with 20% normal serum for 50 minutes
and then with the primary antibody overnight at 4°C.
The antibodies against ER, PR, HER2, Ki67, p53, and
neogenin were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and diluted according to the
manufacturer’s instructions. On the following day, the
sections were washed with PBS thrice and then processed
using an ultrasensitive TM S-P kit (Maixin Biotechnology,
Fuzhou, China). After washes in PBS, the color reaction
was developed using a 3,3'-diaminobenzidine kit (Maixin
Biotechnology). The sections were counterstained with
hematoxylin and covered with a coverslip.
The stained tissue sections were reviewed and scored
independently by two pathologists (Drs Yang Hua and
Chen Guiqiu). The proportion of tumor cells was scored
as follows: none (no positive tumor cells), weak (<10%
positive tumor cells), moderate (10 to 50% positive
tumor cells), and strong (>50% positive tumor cells). ER
and PR positivity was defined as strong nuclear staining
in at least 3/8 of the tumor cells reviewed. HER2/neu
positivity was defined as strong (3+) membranous stai-
ning in at least 10% of tumor cells, whereas scores of 0
to 2+ were regarded as negative.
RNA isolation, reverse transcription, and quantitative
real-time PCR
Total cellular RNA was isolated from frozen tissues
using Trizol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol and was then
incubated with DNase I (Invitrogen) to remove po-
tentially contaminating genomic DNA. After purifica-
tion, these RNA samples (5 μg each) were subjected to
cDNA synthesis using an M-MLV reverse transcriptase
kit (Promega, Madison, WI, USA). Next, these cDNA sam-
ples underwent quantitative PCR amplification using a
StepOnePlus™ Real-Time PCR System (TaKaRa, Dalian,
China). Primers for neogenin were 5'-ACA TGC TGC
ACT GAT CAC CA-3' and 3'-TCA TAG GTG GGA GGT
CCT GG-5'; for GAPDH were 5'-TGA TGA CAT CAA
GAA GGT GGT GAA G-3' and 5'-TCC TTG GAG GCC
ATG TGG GCC AT-3'. PCR conditions were set as
follows: denaturation at 95°C for 5 minutes, followed by 40
cycles of 95°C for 5 seconds, 60°C for 10 seconds, and
72°C for 30 seconds, and an additional cycle at 85°C for
30 seconds to measure the SYBR Green fluorescence.
Finally, the melting-curve was generated by slowly heating
the PCR reactions to 95°C (by 0.3°C per cycle) while simul-
taneously measuring SYBR Green signal intensity. Relative
mRNA expression of neogenin in all the tissue samples
was normalized to that of GAPDH using the equation of
2−ΔΔ CT.
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SPSS18.0 software (SPSS, Chicago, IL, USA) was used to
statistically assess the P value. Measurement data were
analyzed by Student’s t-test, while categorical data were
analyzed by the chi-square test. Differences were consi-
dered statistically significant at P < 0.05.
Results
Differential expression of neogenin in breast cancer and
its distant non-cancerous tissues
We first detected expression of neogenin protein using
immunohistochemical staining in 54 breast cancer and
distant normal tissue samples. The results were scored
as none, weak, moderate, and strong neogenin staining
of epithelial cells according to the assessment of two in-
dependent pathologists. Neogenin protein was strongly
or moderately expressed in the cytoplasm of the distant
non-cancerous cells (Figure 1A). In contrast, neogenin
protein was weakly or not stained in the cytoplasm of
breast cancer cells (51/54, 94.4%; Figure 1B), among
which 13 breast cancer cases did not express neogenin
protein at all. (13/54, 24.1%; Figure 1C).
We then assessed neogenin mRNA expression in these
tissue samples and found that the level of neogenin
mRNA was significantly lower in breast cancer tissues
than in the matched distant non-cancerous tissues (51/
54, 94.4%; Figure 1D).Figure 1 Differential expression of neogenin mRNA and protein in bre
(A) Immunohistochemistry; a representative case showing strong expressio
200× magnification. (B) Immunohistochemistry; a representative case show
tissues (n = 51). 200× magnification. (C) Immunohistochemistry; a represen
cancer tissue (n = 13). (D) Quantitative real-time PCR; 51 out of 54 cases of
to that of the matching distant non-cancerous tissue. The level of neogenin
as a control.Association of neogenin expression with clinicopathological
parameters from breast cancer patients
We then associated the expression of neogenin protein
with clinicopathological parameters from breast cancer
patients (Table 1). The results show that neogenin expres-
sion is inversely associated with breast cancer grade; that
is, grade III breast cancer expressed less neogenin than
grade I-II (Figure 2A,B). Similar findings were observed
with regard to neogenin mRNA expression (P < 0.05;
Figure 2C). However, there was no association between
neogenin expression and other clinicopathological para-
meters, such as tumor size, lymph node status, vascular
invasion status, breast cancer subtype, TNM stage, and
biomarker (ER, PR, HER-2, and Ki67).
Discussion
To date, neogenin expression has been shown to be down-
regulated in a variety of human cancers such as glioblas-
toma [26], colon cancer [27], prostate cancer [28], and
breast cancer [24]. In the original neogenin cloning and
screening study, Meyerhardt and colleagues [13] reported
no alteration in neogenin expression in more than 50 dif-
ferent human cancer cell lines, including breast cancer cell
lines. Later, Lee and colleagues [23] measured expression
of neogenin in breast cancer cell lines and in eight
matched breast cancer and adjacent non-cancerous tissues
using Western blot, and in only breast cancer tissues byast cancer and in matching distant non-malignant tissues.
n of neogenin protein in the cytoplasm of distant non-cancerous tissue.
ing weak expression of neogenin in the cytoplasm of breast cancer
tative case showing negative expression of neogenin protein in breast
breast cancer tissue showed a low level of neogenin mRNA compared
expressed in each distant non-cancerous tissue was normalized to 1




N (%) Expression of neogenin
mRNA level mean ± SD
Age (years) ≥65 4 (7.4) 0.042 ± 0.035 0.060
<65 50 (92.6) 0.270 ± 0.323
Tumor size (cm) ≤2.00 24 (44.4) 0.298 ± 0.373 0.959
2.01-5.00 26 (48.1) 0.217 ± 0.280
≥5.00 4 (7.4) 0.372 ± 0.412
Histology grade I 1 (1.9) 0.132 ± 0 0.032
II 29 (53.7) 0.330 ± 0.343
III 24 (44.4) 0.192 ± 0.313
Stage I 12 (22.2) 0.206 ± 0.319 0.818
II 19 (35.2) 0.292 ± 0.322
III 14 (25.9) 0.254 ± 0.357
IV 9 (16.7) 0.302 ± 0.368
Lymph node metastasis Yes 35 (64.8) 0.320 ± 0.356 0.16
No 19 (35.2) 0.164 ± 0.257
Vascular invasion Yes 38 (70.4) 0.272 ± 0.357 0.755
No 16 (29.6) 0.247 ± 0.268
Subtype Luminal A 13 (24.1) 0.407 ± 0.400 0.484
Luminal B 14 (25.9) 0.217 ± 0.314
H type 14 (25.9) 0.199 ± 0.236
TNBC 13 (24.1) 0.244 ± 0.356
ER + 27 (50) 0.309 ± 0.364 0.387
- 27 (50) 0.221 ± 0.295
PR + 21 (38.9) 0.279 ± 0.318 0.908
- 33 (61.1) 0.256 ± 0.344
HER2 + 21 (38.9) 0.239 ± 0.290 0.918
- 33 (61.1) 0.281 ± 0.358
Ki67 + 39 (72.2) 0.256 ± 0.333 0.128
- 15 (27.8) 0.287 ± 0.335
p53 + 21 (38.9) 0.308 ± 0.371 0.292
- 33 (61.1) 0.237 ± 0.305
ER, estrogen receptor, HER-2, human epidermal growth factor-2; PR, progesterone receptor; TNBC, triple negative breast cancer.
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was downregulated in both breast cancer cell lines as well
as cancerous tissues and concluded that neogenin expres-
sion was inversely correlated with mammary carcinogen-
icity. Our current data support this and other previously
published data [24] in that we have found an association
between neogenin expression and breast cancer grade. We
observed no neogenin expression in higher histological
grade breast cancer compared to lower grade tumors,
which is consistent with a study of glioma [22] where
neogenin expression was inversely associated with histo-
logical grade of that cancer. Neogenin expression has
been reported to be even lower in recurrent glioma casescompared to that of their primary tumors [22]. The histo-
logical grading system in breast cancer is based on diffe-
rentiation of tumor cells, which is an important factor in
predicting prognosis of breast cancer patients and tumor
aggressiveness. Thus, we speculate that breast cancer with
lower neogenin expression in the high histological grade
might be more likely to recur and/or have a worse prog-
nosis. However, the majority of our patients had grade II
and III breast cancers which precluded precise evaluation
of neogenin expression in grade I breast cancer. Future
studies should recruit patients with this breast cancer
grade to further confirm that neogenin expression is asso-
ciated with breast cancer grade.
Figure 2 Association between neogenin expression and clinicopathological parameters from breast cancer patients. (A) Expression of
neogenin in histology grade II breast cancer tissue (n = 29). 200× magnification. (B) Neogenin expression in histology grade III breast cancer tissue
(n = 24). 200× magnification. (C) Expression of neogenin mRNA in different histological grades of breast cancer.
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genin expression was particularly low in the four patients
who were 65 years or older. In parallel with our findings,
Bondy and colleagues [29] also showed that minimum
levels of neogenin appeared in older glioma patients with
poor prognosis. As older patients frequently have sys-
temic diseases after being diagnosed with breast cancer,
treatment of older patients is conservative compared to
younger ones [30]. Thus, neogenin should be further
evaluated as a potential biomarker for older breast can-
cer. Based on our clinical experiences, malignancy of
breast cancer is closely associated with tumor size, sub-
type, TNM stage, lymph node metastasis, vascular inva-
sion, and expression of other biomarkers (such as ER,
PR HER-2, and Ki67); however, we failed to find any
statistical significance between neogenin expression and
these prognostic factors. This indicates that neogenin ex-
pression and its functions warrant further investigation
in breast cancer. A previous study showed that the func-
tion of neogenin in normal breast development is to
guide cap cells and luminal cells into juxtaposition du-
ring the adolescent development period [22]. Although
the combination of netrin-1 and neogenin plays a sig-
nificant role during this process, the role of neogenin in
breast cancer remains to be determined. It has pre-
viously been shown that neogenin might function as an
independent receptor in breast cancer to suppress tumor
development [24]. When neogenin levels are down-
regulated, neogenin-induced apoptosis could be inter-
rupted which could, in turn, lead to cancer development
[20,31]. Similarly, other studies suggest that neogenincould induce chemoattraction or chemorepulsion after
binding to ligands such as netrin-1 and RGM to influence
tumor cell migration and invasion [21,32]. In addition, we
have shown in the current study that neogenin expression
is only marginally associated with lymph node metastasis
of breast cancer.
Conclusions
As such, we hypothesize that the level of neogenin expres-
sion could be altered during tumorigenesis and that a lack
of neogenin expression could promote tumorigenesis early
in the process but that, following tumor formation, certain
tumor cells may re-express neogenin protein to promote
tumor cell migration and metastasis. However, further
studies are needed to clarify the function of neogenin as
well as the cause of lost neogenin expression in breast can-
cer before neogenin can be established as a biomarker for
breast cancer diagnosis.
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